Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Salzer

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Strahlentherapie|November 1, 1975
[Pollen diet as an adjuvans of radiotherapy in gynecologic carcinomas]P Hernuss, E Müller Tyl, H Salzer, et al.
Infection|January 1, 2013
Which lumen is the source of catheter-related bloodstream infection in patients with multi-lumen central venous catheters?R Krause, T Valentin, H Salzer, et al.
Journal of Perinatal Medicine|January 1, 1995
Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytesM Schoderbeck, B Auer, E Legenstein, et al.
Wiener Klinische Wochenschrift|August 3, 1990
[The value of surgical staging in the early stages of ovarian carcinoma]H Salzer, P Sevelda, H Genger, et al.
Human Reproduction (Oxford, England)|September 20, 2012
Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequencesG Hudelist, N Fritzer, A Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatinCh Dittrich, P Sevelda, H Salzer, et al.
Wiener Klinische Wochenschrift|January 1, 1993
[Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]P Sevelda, C Kurz, A Obermair, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1997
[Survival prognosis in ovarian carcinoma Figo stages III and IV: 1980-1985 versus 1986-1993. A comparison of 2 treatment periods]G Knappitsch, K Gruböck, H Salzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patientsC Dittrich, M Baur, N Vavra, et al.
Cancer Letters|April 30, 1990
Analysis of factors influencing clonogenic growth in vitro of cells from ovarian carcinoma patientsC Dittrich, E Dittrich, F Wrba, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Strahlentherapie|November 1, 1975
[Pollen diet as an adjuvans of radiotherapy in gynecologic carcinomas]P Hernuss, E Müller Tyl, H Salzer, et al.
Infection|January 1, 2013
Which lumen is the source of catheter-related bloodstream infection in patients with multi-lumen central venous catheters?R Krause, T Valentin, H Salzer, et al.
Journal of Perinatal Medicine|January 1, 1995
Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytesM Schoderbeck, B Auer, E Legenstein, et al.
Wiener Klinische Wochenschrift|August 3, 1990
[The value of surgical staging in the early stages of ovarian carcinoma]H Salzer, P Sevelda, H Genger, et al.
Human Reproduction (Oxford, England)|September 20, 2012
Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequencesG Hudelist, N Fritzer, A Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatinCh Dittrich, P Sevelda, H Salzer, et al.
Wiener Klinische Wochenschrift|January 1, 1993
[Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]P Sevelda, C Kurz, A Obermair, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1997
[Survival prognosis in ovarian carcinoma Figo stages III and IV: 1980-1985 versus 1986-1993. A comparison of 2 treatment periods]G Knappitsch, K Gruböck, H Salzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patientsC Dittrich, M Baur, N Vavra, et al.
Cancer Letters|April 30, 1990
Analysis of factors influencing clonogenic growth in vitro of cells from ovarian carcinoma patientsC Dittrich, E Dittrich, F Wrba, et al.
Pageof 18